Study summary

Vidofludimus calcium: phase 3 results due, after a miss in progressive MS

Vidofludimus calcium · About 2,200 people across two trials · Top-line results expected by the end of 2026

What was tested

Vidofludimus calcium, a daily pill, against placebo in two large relapsing MS trials (ENSURE-1 and ENSURE-2).

What they found

Both phase 3 trials are fully enrolled.
Phase 2 showed fewer MRI lesions in relapsing MS.
A separate trial in progressive MS (CALLIPER) missed its main goal of slowing brain tissue loss.

What it means

A possible gentler pill option for relapsing MS if phase 3 is positive.

Multiple Sclerosis News Today ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.